Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration
Objective: To determine the relationship between synucleinopathy, neuroinflammation and nigrostriatal degeneration using the rat α-syn PFF model. Background: No therapy exists to halt or slow…In silico predictive analytics: accelerating identification of potential disease-modifying compounds for Parkinson’s disease
Objective: To use an in silico screen to identify compounds that have potential to reduce α-synuclein (aSyn) oligomers and are amenable to drug repurposing for…CSF, plasma and saliva alpha-Synuclein in moderately advanced Parkinson’s disease cohort: the BioFIND study
Objective: To test if alpha-synuclein (α-syn) levels in CSF, plasma and saliva predict PD status in the BioFind cohort, and to test whether α-syn levels…Alpha-synuclein enhances histone H3 lysine-9 dimethylation
Objective: To explore the nuclear function of alpha-synuclein (αS). Background: αS is a protein linked to Parkinson’s disease (PD) and related neurodegenerative disorders. It is…Salivary Alpha-Synuclein in Aging
Objective: We measured alpha-synuclein total (a-syntotal) and alpha-synuclein oligomers (a-synolig) concentration in 70 healthy subjects, of different ages (from 18 to 88 years old) to…Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia
Objective: This is a retrospective biomarker study of an open-label clinical study to examine the safety and efficacy of lower doses (<50% of CML dose)…Extracellular alpha-synuclein internalizes into cells by hijacking endocytic trafficking of dopamine transporter
Objective: The main purposes of this study were to: 1) investigate the possible effect of extracellular alpha-synuclein (aSYN) on the endocytic rate of dopamine transporter…Exposure to bifenthrin contributes to Parkinson’s disease in mouse model
Objective: To explore the relationship between pyrethroid bifenthrin and Parkinson’s disease on mouse model. Background: Pyrethroid is now widely used on account of its high…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…New device HANABI (HANdai Amyloid Burst Inducer) is a rapid and sensitive detecting system of α synuclein fibril in CSF from Parkinson’s disease patients
Objective: Early diagnosis for PD is disturbed by the lack of sensitive and objective detection of accumulated αSyn in the patient’s brain. Recently, Real-Time Quaking-Induced…
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 70
- Next Page »